Efficacy and safety of the intensive dose of rosuvastatin 40mg/day in patients with acute coronary syndrome and at high risk of cardiovascular disease-ROSUVEES-2

Randomized clinical trials have established the benefits of statin therapy in acute coronary syndromes (ACS) via their pleiotropic effects. This was a 12-week, open-label, multicenter, postmarketing observational study evaluating the efficacy and safety of rosuvastatin 40 mg/day in very high-risk or...

Full description

Saved in:
Bibliographic Details
Published in:Indian heart journal 2016-11, Vol.68 (6), p.766-771
Main Authors: Shah, Chetan P., Shah, Bhaskar P., Dani, Sameer I., Channa, B.B., Lakshmanan, S.S., Krishnamani, N.C., Mehta, Ashwani, Moorthy, P.
Format: Article
Language:English
Subjects:
Acute coronary syndrome
Acute Coronary Syndrome - blood
Acute Coronary Syndrome - drug therapy
Acute Coronary Syndrome - mortality
Administration, Oral
Adult
Aged
Cholesterol, LDL - blood
Cholesterol, LDL - drug effects
Dose-Response Relationship, Drug
Female
Follow-Up Studies
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors - administration & dosage
India - epidemiology
LDL-C
Male
Middle Aged
Pleiotropic
Risk Factors
Rosuvastatin
Rosuvastatin Calcium - administration & dosage
Statins
Survival Rate - trends
Time Factors
Treatment Outcome
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Randomized clinical trials have established the benefits of statin therapy in acute coronary syndromes (ACS) via their pleiotropic effects. This was a 12-week, open-label, multicenter, postmarketing observational study evaluating the efficacy and safety of rosuvastatin 40 mg/day in very high-risk or high-risk Indian patients according to NCEP ATP III guidelines. One hundred and sixty two patients (age: 30 to 69 years) with evidence of coronary artery disease, hospitalized with chest pain with/without electrocardiogram changes and with non-ST segment elevation ACS and ST segment elevation ACS who received optimal reperfusion therapy were enrolled. The primary endpoint was the percent change from baseline in low-density lipoprotein cholesterol (LDL-C) levels at 6 and 12 weeks of treatment. Other lipid parameters, high sensitive C-reactive protein (hsCRP), glycosylated hemoglobin, and clinical biochemical parameters were also assessed. At 12 weeks, intensive therapy with rosuvastatin 40mg/day significantly reduced LDL-C (p
ISSN:0019-4832
DOI:10.1016/j.ihj.2016.09.002